Navigation Links
Lexicon to Provide Second Quarter 2012 Financial Results
Date:7/24/2012

The Woodlands, Texas, July 24, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it will release its second quarter 2012 financial results on Tuesday, July 31, 2012 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss financial results for the quarter and program status at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 13784620. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on Lexicon's corporate website at www.lexpharma.com through August 31, 2012.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
2. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
3. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
6. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
7. Lexicon to Provide First Quarter 2012 Financial Results
8. STAAR Surgical Provides Outlook On Second Quarter 2012 Financial Results
9. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced ... in a precise manner using the myDNAge ™ test. Based on ... of human genetics and biostatistics at the David Geffen School of ... Zymo Research,s proprietary DNAge ™ technology is used to analyze DNA ... ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
(Date:7/10/2017)... -- US medical equipment and supply demand is forecast to ... Medical Equipment & Supplies: United States , a ... in demand for medical services – driven in large ... by gains in disposable personal income – will boost ... will also drive sales as providers and patients seek ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... Patients with missing teeth now ... office visit from Dr. Alejandro Kovacs. Dr. Kovacs is a board-certified periodontist and ... including Teeth-in-a-Day® dental implants in Longview, TX. , During traditional ...
(Date:7/27/2017)... Aliso Viejo, CA (PRWEB) , ... July 27, 2017 , ... ... Final Cut Pro X . This Final Cut Pro X exclusive features transitions that ... horizontally, and add rotation to the transition using intuitive drop-down menus. TransPanel Volume 4 ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... of a secure cloud-based polysomnography (PSG) distributed scoring solution to its healthcare management ... and sleep care management. The speed and functionality of scoring in the cloud ...
(Date:7/27/2017)... ... , ... SSCI, a division of Albany Molecular Research, Inc. ... a milestone achievement. , As an industry-leading provider of solid-state ... as expert and fact witnesses to assist our clients to perform infringement analyses, ...
(Date:7/27/2017)... ... July 27, 2017 , ... The Los Angeles leg of the US movie premier ... 7:00pm and will be held at the Clive Davis Theater inside the Grammy Museum Located ... chronicles the story of the iconic Welsh rock musician, Mike Peters (of The Alarm), his ...
Breaking Medicine News(10 mins):